Gentize Biopharma, a clinical-stage vaccine developer based in Nanjing, has reportedly raised close to RMB 100 million (USD 13.64 million) in a Pre-Series A financing round. The round was solely funded by Hyfinity Investments, highlighting the investor’s confidence in Gentize’s innovative vaccine portfolio.
Financing and Future Plans
The proceeds from this financing round will be directed towards Phase I and II clinical studies for Gentize’s innovative adjuvant herpes zoster vaccine, clinical filing for the recombinant influenza vaccine, and the expansion and construction of its technology platform. This strategic use of funds aims to accelerate the development of Gentize’s vaccine pipeline, bringing new and improved treatments to market.
Product Pipeline and Company Background
Founded in 2018, Gentize Biopharma has established a robust product pipeline that includes an innovative adjuvant herpes zoster vaccine, a recombinant influenza vaccine, an improved two-dose rabies vaccine, and a therapeutic tumor vaccine. These products are at various stages of development, ranging from clinical trials to IND filing and pilot production. Gentize’s commitment to innovation and its diverse vaccine portfolio position it as a key player in the biopharma sector, particularly in the development of next-generation vaccines.-Fineline Info & Tech
